Advanced Cardiac Admissions Protocol (ACAP)
Atrial Fibrillation/Aflutter Pathway (RACE)
To be completed on patients with a diagnosis of AFib or AFlutter

**ADMISSION DIAGNOSIS:** (Please mark all that apply)
- [ ] Atrial Fibrillation/Flutter
- [ ] ACS
- [ ] Heart Failure
- [ ] Other Cardiac Causes

**INITIAL ASSESSMENT:**
- [ ] 12 lead EKG within 10 mins; Vital Signs, H&P
- [ ] Labs: BMP, CBC, Mg, PT, PTT, INR, TSH
- [ ] Is patient on Warfarin?  YES  NO
- [ ] Is Patient Stable?  YES  NO
- [ ] Known Atrial Fibrillation/Flutter
- [ ] New Onset Atrial Fibrillation/Flutter

Consider Etiology of Atrial Fibrillation/Flutter

- [ ] Non-Cardiac Etiology
- [ ] Thyroid or Trauma
- [ ] Recreational Drug Use
- [ ] Alcohol
- [ ] Pulmonary Disease
- [ ] Sepsis/Infection

Type of Arrhythmia:  A. Fib  A. Flutter
Duration of Arrhythmia:  < 48 hours  > 48 hours  Unknown

< 48 Hrs
- Sinus Rhythm Restored after Cardioversion.
- First/Single episode of Atrial Fibrillation.
- Failed Cardioversion >> TTE
  - Heparin Therapy
  - Rate Control
  - Antiarrrhythmic Medications
- Evidence of CVD:  CHF  CAD  HTN

> 48 Hrs or Unknown

- Heparin Therapy
- TEE
- Clot >> Warfarin x 3 wks
- No Clot >> Cardioversion + Warfarin x 4 wks.

R  Rate Control, HR < 30 bpm
( < 120 bpm with exercise)

Beta Blockers:
- [ ] Metoprolol .....................mg po bid
- [ ] Esmolol .....................mg/kg IV

Calcium Channel Blockers:
- [ ] Diltiazem ..............mg po (daily/q12/q6)
- [ ] Verapamil .............mg po (daily, q12)
- [ ] Digoxin ......................mg po daily

AC  Anticoagulation Therapy, based on Thromboembolic risk assessment
- Weight adjusted Heparin
- Low Molecular Weight Heparin
- Warfarin, target INR
- Aspirin

E  EP/Antiarrrhythmic Medication

Class IC
- [ ] Flecainide ..................mg po bid
- [ ] Propafenone ..............mg po q8h

Class III
- [ ] Amiodarone ................mg po daily
- [ ] Sotalol .....................mg po bid
- [ ] Dofetilide ......................mg po bid

Resident: ________________________________________________________

Approved  9/14/2005